Global Lyophilization Equipment Market Projected to Reach $12.21 Billion by 2030, Driven by Biopharma Expansion

Date: June 24, 2026

The global lyophilization equipment market is experiencing robust growth, with market size expected to reach $12.21 billion by 2030, according to a comprehensive market report published by The Business Research Company.

The market was valued at $7.32 billion in 2025 and is projected to grow to $8.13 billion in 2026, representing a compound annual growth rate (CAGR) of 11.1%.

Forecast period growth is attributed to increasing investment in biopharmaceutical and biotechnology sectors, rising demand for continuous freeze-drying technologies, expansion of contract research organizations, and adoption of automated lyophilization systems.

The growth in the historic period can be traced to rising biopharmaceutical production, expansion in vaccine manufacturing, growing demand for stable drug formulations, adoption of freeze-drying in the food industry, and advancements in lab-scale lyophilization equipment.

One of the key drivers is the rising prevalence of chronic diseases, which increases demand for stable biopharmaceuticals and injectable drugs that rely on freeze-drying for long-term preservation.

For example, data from the UK's National Health Service shows that in 2023, 3,615,330 patients registered with primary care physicians were diagnosed with non-diabetic hyperglycemia (pre-diabetes), an 18% increase from 2022's 3,065,825 cases.

Major trends shaping the market include increased demand for heat-sensitive drug preservation, growth in biopharmaceuticals and vaccines, miniaturization of laboratory freeze dryers, automation in freeze-drying processes, and expansion into food and nutraceutical applications.

North America is expected to remain the largest regional market through 2025, driven by strong R&D investment and expansion in biotech and pharmaceutical manufacturing.

U.S. manufacturers are expanding production capacity to maintain competitive advantages, with IMA Life North America announcing a new freeze-dryer manufacturing facility in Tonawanda, New York.

The growing number of cancer patients in the U.S. — projected to reach approximately 2,041,910 new cases and 618,120 deaths by 2025, according to the American Cancer Society — further drives investment in lyophilization equipment for stable injectable drug formulations.

Industrial-scale freeze-dryers hold the largest market share, driven by widespread adoption in commercial production of pharmaceuticals, biopharmaceuticals, vaccines, and freeze-dried foods.

These systems offer high capacity, consistent batch quality, regulatory compliance, and advanced automation features essential for large-scale manufacturing.

The increasing investments in biopharmaceutical manufacturing facilities and contract development and manufacturing organizations, coupled with rising demand for sterile injectables, continue to consolidate this segment's dominance.

For international freeze-dryer buyers and industry stakeholders, these market dynamics highlight several key considerations: the growing emphasis on automated and continuous freeze-drying technologies to improve throughput and reduce cycle times; the importance of scalable equipment that can transition seamlessly from R&D to production; and the expanding application scope beyond traditional pharmaceuticals into food processing and nutraceuticals — all of which point toward sustained investment and innovation in the sector through 2030.